LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-12. Anything still debated is marked as such rather than presented as settled.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Over the following week, the secondary buds branch into tertiary buds, about ten on each side. From the sixth week to the sixteenth week, the major elements of the lungs appear except the alveoli. From week 16 to week 26, the bronchi enlarge and lung tissue becomes highly vascularised. Bronchioles and alveolar ducts also develop. By week 26, the terminal bronchioles have formed which branch into two respiratory bronchioles. During the period covering the 26th week until birth the important blood–air barrier is established. Specialised type I alveolar cells where gas exchange will take place, together with the type II alveolar cells that secrete pulmonary surfactant, appear. The surfactant reduces the surface tension at the air-alveolar surface which allows expansion of the alveolar sacs. The alveolar sacs contain the primitive alveoli that form at the end of the alveolar ducts, and their appearance around the seventh month marks the point at which limited respiration would be possible, and the premature baby could survive.
== Further reading == Schmidt, Eckart W. (2022). "1,3,5,7-Tetranitro-1,3,5,7-tetraazacyclooctane, Octogen (HMX)". Nitramines. Encyclopedia of Liquid Fuels. De Gruyter. pp. 4327–4371. doi:10.1515/9783110750287-035. ISBN 978-3-11-075028-7.
The Hollywood Reporter's Stephen Dalton wrote that the "dark, ironic, very British humour of the original strip" was largely absent from the film and that "[t]he limited location, computer game-style plot and muted humour" of the film might disappoint some fans of the comic. Dalton also said that Urban's performance, while close to the comic, lacked something. Overall Dalton said, "[p]itched at the right level to please original fans, but still slick and accessible enough to attract new ones, [Dredd] feels like a smart and muscular addition to the sci-fi action genre." The visual effects and slow-motion sequences induced by Slo-Mo received broad praise. Berkshire said that they are notable and eye-catching with "impressively utilised 3D." Hewitt said the visuals were "genuinely surreal splashes of heightened colour that ... don't outstay their welcome. The film's use of 3D is often excellent (including the credits) and it really comes to life in the Slo-mo scenes". Dalton said the film "constantly impresses on a visual level, with a gritty style more akin to cult hits like District 9 or 28 Days Later than to standard Hollywood comic-book blockbusters." Dalton said, "[Mantle's] first venture into 3D is a blaze of saturated colours, gorgeous high-resolution close-ups and dazzling slow-motion sequences." Dredd won The Art of 3D award at the 2013 Empire Awards, and was nominated for Best British Film and Best Science-fiction/Fantasy. Judge Dredd creator John Wagner, who had been critical of the 1995 adaptation, gave a positive review of Dredd. He said: "I liked the movie.
== OECD's Mutual Acceptance of Data (MAD) == Sources: The chemicals industry, which includes industrial chemicals, pharmaceuticals, pesticides, biocides, food and feed additives, and cosmetics, ranks as one of the largest industrial sectors in the world. Harmonizing national approaches (the OECD's key mission) to chemical regulation offers several benefits: it streamlines requirements for industry, provides governments with a common framework for collaboration, and reduces trade barriers. Simultaneously, the OECD adopted 1) the Mutual Acceptance of Data (MAD) Directive system; and 2) the OECD Guidelines for Testing Chemicals and OECD Principles of Good Laboratory Practice (GLP), to be required by regulators globally (and to which the MAD Directive applies). These two simultaneous acts were instrumental in achieving this global harmonization. The MAD system aims to avoid conflicting or redundant national regulations, foster cooperation among national authorities, and eliminate trade barriers. Under this system, OECD countries and full adherents agree that safety tests conducted according to OECD Test Guidelines and Good Laboratory Practice in one country should be accepted by others for assessment purposes—a principle known as "tested once, accepted for assessment everywhere." This approach saves the chemicals industry from the expense of duplicative testing for products marketed in multiple countries. Crucially, though a receiving government must accept a TG-performed study, it retains the discretion to rely on other data (e.g.
Sources: en.wikipedia.org
Tyrannosaurus is the type genus of the superfamily Tyrannosauroidea, the family Tyrannosauridae, and the subfamily Tyrannosaurinae; in other words it is the standard by which paleontologists decide whether to include other species in the group. Other members of the tyrannosaurine subfamily include the North American Daspletosaurus and the Asian Tarbosaurus, both of which have occasionally been synonymized with Tyrannosaurus. Tyrannosaurids were once commonly thought to be descendants of earlier large theropods such as megalosaurs and carnosaurs, although more recently they were reclassified with the generally smaller coelurosaurs. The earliest tyrannosaur group were the crested proceratosaurids, while later and more derived members belong to the Pantyrannosauria. Tyrannosaurs started out as small theropods; at least some became larger by the Early Cretaceous. It is likely that tyrannosauroids rose to prominence after the decline in allosauroid and megalosauroid diversity seen during the early stages of the Late Cretaceous. Tyrannosauroids are characterized by their fused nasals and dental arrangement. Pantyrannosaurs are characterized by unique features in their hips as well as an enlarged foramen in the quadrate, a broad postorbital and hourglass shaped nasals. Some of the more derived pantyrannosaurs lack nasal pneumaticity and have a lower humerus to femur ratio with their arms starting to see some reduction. Some pantyrannosaurs started developing an arctometatarsus.
=== Surgery === A surgery of any type inherently carries more risks when done on a patient who has (especially moderate to severe) OI. Skeletal deformities and dentinogenesis imperfecta may hinder access to the airway. Use of, and weaning off of, mechanical ventilation is also more challenging to carry out on patients with OI. During the procedure itself or the healing process, defective OI collagen may lead to bleeding diatheses. The safety of anesthesia is also of more concern among patients with OI, with anesthetic complications 5.6x more likely to occur when the patient has OI type III. A unique concern of anesthesia in OI is perioperative fracture—fractures sustained due to patient transfer and airway access techniques that, while routine when a patient's bones are strong, may cause injury with brittle OI bones. As an example, due to a 1972 report of a humerus fracture from a sphygmomanometer cuff sustained in an OI patient during surgery, blood pressure monitoring protocols are often modified for patients with OI, with neonatal size cuffs and machine settings being used even in adults; further, the least deformed of the patient's limbs is preferred to receive the cuff.
An addition to the Special Metallurgical building weapon component production facility was completed at the end of 1964 for 238Pu heat source fuel fabrication. A temporary fuel production facility was also installed in the Research Building in 1969 for Transit fuel fabrication. With completion of the weapons component project, the Special Metallurgical Building, nicknamed "Snake Mountain" because of the difficulties encountered in handling large quantities of 238Pu, ceased operations on June 30, 1968, with 238Pu operations taken over by the new Plutonium Processing Building, especially designed and constructed for handling large quantities of 238Pu. Plutonium-238 is given the highest relative hazard number (152) of all 256 radionuclides evaluated by Karl Z. Morgan et al. in 1963.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.